ReviewBMC cancer2025
Anoikis resistance and cancer.
Review in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Anoikis in cancer: molecular mechanisms, resistance, and therapeutic strategies.Apoptosis : an international journal on programmed cell death · 2026Review
- Nitric Oxide, Reactive Oxygen Species, and Focal Adhesion Kinase Mediate Anoikis Resistance in A375 and SK-MEL-28 Human Melanoma Cells.Antioxidants (Basel, Switzerland) · 2026Article
- Circulating Tumor Cells in Soft Tissue Sarcoma: Current Evidence and Clinical Implications.Cancers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Normal epithelial cells detach from extracellular matrix during normal homeostasis by a selective process called epithelial extrusion. Thereafter, they undergo apoptosis, in a phenomenon called anoikis. Metastatic tumor cells, however, detach from normal epithelial tissues or primary tumors and survive in circulation, sometimes long enough to disseminate and colonize metastatic sites. The thirty years since the discovery of anoikis, exciting progress has been made in understanding anoikis mechanisms and the diverse mechanisms by which tumor cells evade or subvert them. Previous reviews have summarized earlier aspects of anoikis, including integrin-apoptosis signaling, Epithelial-Mesenchymal Transition and intracellular metabolism. Based on recently emerging work, we focus here on four issues that advance our conceptual understanding significantly: How do cytoskeleton and signaling interface so as to control anoikis? How is epithelial extrusion programmed in normal vs. cancer cells, upstream of anoikis? What is the role of translational regulation in anoikis? How do tumor cell-blood cell interactions affect anoikis? This review summarizes recent observations that inform these issues, and provides perspective on future problems to be investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.